Clinical Trial Update: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates pelabresib in combination with ruxolitinib for myelofibrosis and is currently recruiting across primary MF and MF arising after pol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pelabresib (pelabresib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Status: RECRUITING